StoneJH, TuckwellK, DimonacoS. Trial of tocilizumab in giant cell arteritis. N Engl J Med2017; 7: 317–28.
2.
UnizonySH, DasguptaB, FishelevaE. Design of the tocilizumab in giant cell arteritis trial. Int J Rheumatol2013;912562.
3.
SmolenJS, AletahaD. Interleukin-6 inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis. The role of acute-phase reactants. Arthritis Rheumatol2011; 63;43–52.
4.
DelecoeuillerieG, JolyP, Cohen de LaraA. Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients). Ann Rheum Dis1988; 47: 733–39.
5.
ProvenA, GabrielSE, OrcesC. Glucocorticoid therapy in giant cell arteritis: Duration and adverse outcomes. Arthritis Rheumatol2003; 49: 703–8.
6.
SamelsonEJ, HannanMT, ZhangY. Incidence and risk factors for vertebral fracture in women and men: 25-year follow-up results from the population-based Framingham study. J Bone Min Res2006; 21: 1207–14.
7.
The European Prospective Osteoporosis Study (EPOS) Group. Incidence of vertebral fracture in Europe: Results from the European Prospective Osteoporosis Study (EPOS). J Bone Min Res2002; 17: 716–24.
8.
De SilvaM, HazlemanBL. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis1986; 45: 136–8.
9.
ButtgereitF, DejacoC, MattesonEL. Polymyalgia rheumatica and giant cell arteritis. A systematic review. JAMA2016; 315: 2442–58.
10.
MahrAD, JoverJA, SpieraRF. Adjunctive methotrexate for treatment of giant cell arteritis. An individual patient data meta-analysis. Arthritis Rheumatol2007; 56: 2789–97.
11.
LangordCA, CuthbertonD, YtterbergSR. A randomised, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol2017; 69: 837–45.
12.
StrangfeldA, RichterA, SiegmundB. Risk of lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs. Ann Rheum Dis2017; 76: 504–10.
13.
StrehlC, BijlsmaJWJ, de WitM. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR taskforce. Ann Rheum Dis2016; 75: 952–7.
